PPARA

PPARα (PPARA) is a ligand-activated nuclear receptor that heterodimerizes with retinoid X receptor (RXR) and binds peroxisome proliferator response elements (PPREs) upstream of target genes to drive transcription, with fatty acids and their derivatives serving as direct activating ligands (PMID:8538617, PMID:7626496). Through this activity it is the master transcriptional regulator of hepatic and systemic lipid handling: it lowers triglycerides by repressing apolipoprotein C-III and inducing lipoprotein lipase, raises HDL via ApoA-I/ApoA-II induction (PMID:10774955), and is required for normal fatty acid and glucose homeostasis across liver, heart, muscle, and adipose tissue, with loss producing hepatic steatosis, hypoglycemia, and hypertriglyceridemia (PMID:16945951, PMID:19357638). PPARα additionally restrains inflammation through PPRE-independent transcriptional outputs, upregulating IκBα to form an autoregulatory loop with NF-κB (PMID:14713228) and inducing the lncRNA Gm15441 to suppress TXNIP-driven NLRP3 inflammasome activation (PMID:33203882). It promotes autophagy, which underlies PPARα-dependent primary ciliogenesis and Aβ clearance (PMID:29771182, PMID:30898012), and it drives hepatocyte proliferation in a hepatocyte-autonomous manner through an E2F8–UHRF1–CDH1 epigenetic axis activating Wnt/Myc signaling (PMID:28082284, PMID:35479397). In human liver it also regulates CYP3A4 expression (PMID:22510778). PPARA expression and activity are controlled by upstream transcription factors KLF5 (activator) and c-Jun (repressor) at its promoter (PMID:26574507), by miRNAs miR-141 and miR-20b post-transcriptionally (PMID:22479552, PMID:34964438), and its transactivation is inhibited by activated AMPK independently of AMPK kinase activity and without altering DNA binding (PMID:21700905).

1. 1995 High

   Established the core molecular machinery: how PPARα converts a signal into transcription by defining its DNA target, dimerization partner, and the nature of its activating ligand.

   Evidence Transactivation and DNA-binding assays showing RXR heterodimerization at PPREs; CHO chimera reporter assays mapping fatty-acid structure-activity

   PMID:7626496 PMID:8538617

   Open questions at the time

   • Endogenous physiological ligand identity not resolved
   • Co-activator/co-repressor recruitment not detailed
2. 1995 Medium

   Showed PPARα activity is constrained by competition within the receptor family, identifying NUC1 (PPARβ/δ) as a repressor titrating a shared limiting factor.

   Evidence Transient transfection reporter and cooperative DNA-binding assays with receptor specificity controls

   PMID:7876127

   Open questions at the time

   • Identity of the titrated activating factor not determined
   • In vivo relevance of the repression not tested
3. 2000 Medium

   Connected PPARα transcriptional outputs to clinically relevant lipoprotein metabolism, providing the mechanistic basis for fibrate triglyceride lowering and HDL raising.

   Evidence Gene expression assays for ApoC-III, LPL, ApoA-I/A-II under fibrate treatment in hepatic systems

   PMID:10774955

   Open questions at the time

   • Direct vs indirect regulation of each target not fully dissected
   • Human in vivo confirmation limited
4. 2003 Medium

   Defined a PPRE-independent anti-inflammatory mechanism, showing PPARα enforces an autoregulatory brake on NF-κB via IκBα induction.

   Evidence Promoter reporter assays with NF-κB/Sp1 element and DRIP250 cofactor requirement analysis

   PMID:14713228

   Open questions at the time

   • Mechanism of cofactor-dependent activation without a PPRE unclear
   • Single-lab promoter analysis
5. 2006 High

   Validated that hepatic loss-of-function phenotypes are specifically attributable to PPARα, distinguishing on-target effects from genetic compensation.

   Evidence Comparison of Ppara knockout vs hepatic siRNA knockdown with transcriptional profiling and metabolic phenotyping

   PMID:16945951

   Open questions at the time

   • Direct target genes not separated from secondary responses
6. 2007 Medium

   Identified an unexpected non-canonical inhibition of PPARα by AMPK acting through its activated conformation rather than kinase activity.

   Evidence PPRE luciferase reporter, EMSA, and dominant-negative/constitutively active AMPK constructs in hepatoma cells

   PMID:21700905

   Open questions at the time

   • Physical basis of conformation-dependent inhibition not resolved
   • In vivo significance untested
7. 2009 Medium

   Demonstrated PPARα is required systemically for lipid and glucose homeostasis across multiple tissues, not just liver.

   Evidence 1H NMR and GC-MS metabolomics in Ppara-null vs wild-type mice across aging and tissues

   PMID:19357638

   Open questions at the time

   • Tissue-specific contributions not separated
   • Causal target genes not identified
8. 2012 High

   Extended PPARα function into xenobiotic metabolism and provided human genetic validation of its control of CYP3A4.

   Evidence shRNA knockdown in primary human hepatocytes, SNP association in a liver bank, and pharmacokinetic confirmation in volunteers

   PMID:22510778

   Open questions at the time

   • Direct binding at CYP3A4 regulatory regions not shown
   • Mechanism of SNP effect on protein level unclear
9. 2012 Medium

   Showed PPARA is a post-transcriptional target whose suppression affects viral biology, linking miR-141-mediated PPARA reduction to HBV replication control.

   Evidence miRNA mimic and PPARA siRNA with luciferase promoter reporter and HBV replication quantification in HepG2

   PMID:22479552

   Open questions at the time

   • Mechanism by which PPARA supports HBV promoter function not defined
   • In vivo relevance untested
10. 2015 High

    Identified the upstream transcriptional control of PPARA itself, with KLF5 activating and c-Jun repressing the promoter to govern cardiac fatty acid oxidation.

    Evidence Direct promoter binding assays, cardiac-specific Klf5 conditional knockout, metabolic flux and echocardiography

    PMID:26574507

    Open questions at the time

    • Generalization beyond cardiomyocytes not established
    • Other promoter regulators not mapped
11. 2017 High

    Dissected cell-type-specific PPARα roles, showing hepatocyte PPARα drives proliferation while macrophage PPARα controls inflammatory cytokine suppression.

    Evidence Hepatocyte- and macrophage-specific conditional Ppara knockouts with Wy-14643, BrdU labeling and cytokine analysis

    PMID:28082284

    Open questions at the time

    • Molecular mediators of proliferation not yet defined at this stage
12. 2018 High

    Linked PPARα to autophagy-dependent organelle biogenesis, establishing that PPARα-driven autophagy is required for primary ciliogenesis.

    Evidence PPARA agonist/antagonist, ppara-/- mice, autophagy knockdown, rapamycin rescue, and starvation studies

    PMID:29771182

    Open questions at the time

    • Direct autophagy gene targets of PPARα not enumerated
    • Mechanism opposing FXR repression unclear
13. 2019 Medium

    Generalized PPARα-driven autophagy to neurodegeneration, showing agonist-induced autophagy enhances Aβ clearance and reverses memory deficits.

    Evidence Agonist treatment with siRNA knockdown, autophagy markers, Aβ ELISA, and behavior in APP-PSEN1ΔE9 mice

    PMID:30898012

    Open questions at the time

    • Direct transcriptional targets driving autophagosome biogenesis unspecified
    • Single-lab finding
14. 2019 Medium

    Revealed a lysosome-to-nucleus feedback whereby lysosomal function sustains PPARA/PGC1α transcription to maintain peroxisomal gene expression.

    Evidence Bafilomycin A1, TFEB knockdown, microarray/qPCR, and PPARA overexpression rescue in AML12 cells

    PMID:31032705

    Open questions at the time

    • Mechanism by which lysosomal status controls PPARA transcription unclear
    • In vivo confirmation lacking
15. 2020 High

    Defined a direct PPARα-driven lncRNA circuit (Gm15441) that restrains the TXNIP–NLRP3 inflammasome during agonism and fasting.

    Evidence ChIP for PPARα binding sites, Gm15441-null mice, and inflammasome/CASP1/IL1B readouts

    PMID:33203882

    Open questions at the time

    • Human orthologous lncRNA mechanism not addressed
16. 2021 High

    Established MIR20B as a post-transcriptional repressor of PPARA controlling hepatic fatty acid oxidation and fibrate response in NAFLD.

    Evidence MIR20B mimic/anti-MIR20B in multiple hepatocyte lines and HFD/MCD mice, luciferase reporter, FA oxidation and mitochondrial biogenesis assays

    PMID:34964438

    Open questions at the time

    • Interplay with other PPARA-targeting miRNAs not resolved
17. 2022 High

    Resolved the molecular mediators of hepatocyte proliferation, defining the E2F8–UHRF1–CDH1 epigenetic axis downstream of PPARα.

    Evidence Agonist treatment, PPARA-deficient mice, E2F8/UHRF1 knockdown, ChIP for H3K9me3 at Cdh1, CDH1 forced expression, Wnt target analysis

    PMID:35479397

    Open questions at the time

    • Direct vs indirect PPARα regulation of E2F8 not fully shown
    • Relevance to human hepatocarcinogenesis untested

• The endogenous physiological ligand of PPARα and the structural basis of its non-canonical regulation (AMPK conformation, PPRE-independent transactivation) remain undefined.
• No defined endogenous activating ligand
• No structural model linking AMPK conformation to PPARα inhibition
• Cofactor logic of PPRE-independent gene induction unresolved